

1 **Title:** Exploring Integrated Environmental Viral Surveillance of Indoor Environments: A
2 comparison of surface and bioaerosol environmental sampling in hospital rooms with COVID-19
3 patients

4
5 **Authors:**

6 Leslie Dietz¹, David A. Constant², Mark Fretz^{3,4}, Patrick F. Horve¹, Andreas Olsen-Martinez¹,
7 Jason Stenson³, Andrew Wilkes⁵, Robert G. Martindale⁶, William B. Messer², Kevin G. Van Den
8 Wymelenberg^{1,3,4}

9
10 **Affiliations:**

11 ¹ Biology and the Built Environment Center, University of Oregon, Eugene, OR, 97403

12 ² Department of Molecular Microbiology and Immunology, Oregon Health & Science
13 University, Portland, Oregon, USA

14 ³ Energy Studies in Buildings Laboratory, University of Oregon, Eugene, OR, 97403

15 ⁴ Institute for Health and the Built Environment, University of Oregon, Portland, OR, 97209

16 ⁵ Healthcare Facilities, Oregon Health & Science University, Portland, Oregon, USA

17 ⁶ Division of Gastrointestinal and General Surgery, School of Medicine, Oregon Health &
18 Science University, Portland, Oregon, USA

19
20 **Corresponding Author(s)**

21 Kevin Van Den Wymelenberg, kevinvdw@uoregon.edu, (541) 346-5647, Biology and the Built
22 Environment Center, University of Oregon, Eugene, OR, 97403, Energy Studies in Buildings

23 Laboratory, University of Oregon, Eugene, OR, 97403, Institute for Health and the Built
24 Environment, University of Oregon, Portland, OR, 97209

25

26 **Author Contributions:**

27 KVDW, RM and WM conceived of the project scope and KVDW oversaw project and
28 manuscript development. RM and KVDW oversaw the institutional review board process and
29 WM and KVDW oversaw the biosafety committee review process. LD and PFH collected all
30 samples. AW, JS, and MF verified supply and return air grille sampling locations. LD & DC
31 processed all laboratory samples at OHSU's BSL-2+ laboratory, and PFH & LD processed all
32 laboratory samples and conducted qRT-PCR at UO BSL-2 laboratory. PFH organized all data,
33 performed all analyses, and developed all graphics. LD, AOM, PFH, and KVDW wrote the
34 initial manuscript and DC and MF provided significant edits to the manuscript. All authors
35 reviewed and approved the final manuscript.

36

37 **Funding:**

38 Funding for this research was partially provided by Thermo Fisher Scientific under award
39 number 4133V0 to the University of Oregon and partially via the OHSU Foundation.

40

41 **Keywords:** SARS-CoV-2, COVID-19, Bioaerosols, Environmental Surveillance, Air Sampling

42

43

44

45

46 **Abstract:**

47 The outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has
48 dramatically transformed policies and practices surrounding public health. One such shift is the
49 expanded emphasis on environmental surveillance for pathogens. Environmental surveillance
50 methods have primarily relied upon wastewater and indoor surface testing, and despite
51 substantial evidence that SARS-CoV-2 commonly travels through space in aerosols, there has
52 been limited indoor air surveillance. This study investigated the effectiveness of integrated
53 surveillance including an active air sampler, surface swabs and passive settling plates to detect
54 SARS-CoV-2 in hospital rooms with COVID-19 patients and compared detection efficacy
55 among sampling methods. The AerosolSense active air sampler was found to detect SARS-CoV-
56 2 in 53.8% of all samples collected compared to 12.1% detection by passive air sampling and
57 14.8% detection by surface swabs. Approximately 69% of sampled rooms (22/32) returned a
58 positive environmental sample of any type. Among positive rooms, ~32% had only active air
59 samples that returned positive, while ~27% and ~9% had only one or more surface swabs or
60 passive settling plates that returned a positive respectively, and ~32% had more than one sample
61 type that returned a positive result. This study demonstrates the potential for the AerosolSense to
62 detect SARS-CoV-2 RNA in real-world healthcare environments and suggests that integrated
63 sampling that includes active air sampling is an important addition to environmental pathogen
64 surveillance in support of public health.

65

66

67

68

69 **Introduction**

70 A global pandemic was declared 12 March 2020 and is ongoing¹. Severe acute respiratory
71 syndrome coronavirus 2 (SARS-CoV-2) causes a respiratory illness known as Coronavirus
72 Disease 19 (COVID-19), which can present with a wide variety of symptoms. If symptomatic,
73 the symptoms can mimic the common cold and be extremely mild, or be quite severe requiring
74 medical attention and even hospitalization. In addition to the symptomatic individuals with
75 COVID-19, it is estimated that more than half of all SARS-CoV-2 transmission is due to
76 asymptomatic individuals².

77
78 Early in the pandemic, public health officials declared droplet spread as the main route of disease
79 transmission³. However, evidence has increasingly implicated inhalation of aerosols in the
80 spread of SARS-CoV-2⁴⁻⁷. Past epidemics of coronaviruses, severe acute Respiratory Syndrome-
81 associated Coronavirus (SARS-CoV) and Middle Eastern Respiratory Syndrome-associated
82 Coronavirus (MERS-CoV), demonstrated the ability of virions to spread in built environments
83 via aerosols⁸⁻¹². Previous work has also demonstrated that SARS-CoV-2 can be transported via
84 aerosols and fomites and remain viable in the air and on surfaces¹³⁻¹⁵. Indoor environments with
85 characteristics such as high occupant density, poor ventilation, or high aerosol generating activity
86 have increased potential for transmission of COVID-19, including from pre-symptomatic or
87 asymptomatic individuals¹⁶⁻¹⁹. Similarly, long-term care facilities (LTCF), hospital care systems,
88 and several other settings that provide services to susceptible occupants are also vulnerable to
89 disease transmission^{16,20-24}. The ability to monitor indoor environments to detect potential
90 shedding from infectious individuals is an important layer of control to prevent or contain
91 outbreaks of highly infectious and deadly illnesses like COVID-19.

92 As a result of the COVID-19 pandemic, there has been increased pressure to innovate current
93 building operational practices, including enhanced air management, and increased motivation to
94 elevate awareness of indoor environmental microbial presence and abundance in general, and
95 specifically to implement ongoing viral surveillance. Environmental surveillance for biological
96 agents is not a new practice. For example, specialized facilities such as military bases and mail
97 distribution centers are monitored for biohazards and biological threat agents such as anthrax and
98 smallpox^{25,26} and water treatment plants monitor for select microorganisms as indicators for
99 drinking water quality²⁷⁻³⁰. Additionally, built environments such as restaurants, food production
100 facilities or hospitals are routinely inspected and sampled for microorganisms to ensure
101 sanitation and cleanliness practices^{31,32}. Environmental microbial samples from indoor surfaces
102 are commonly obtained using swabs^{33,34}. Aerosol particles can be detected through passive air
103 sampling in settling plates (collection onto the surface of a petri dish)^{35,36} or through active air
104 sampling using a vacuum pump to move a known volume of air across a capture mechanism³⁷.
105 Active air samplers span a range of airflow rates, wet and dry media, and physical collection
106 mechanisms including filters, cyclones, impingers and impactors³⁸⁻⁴⁰. Using any of these
107 collection devices, the sampling media can be evaluated for a target pathogen using molecular
108 techniques.

109
110 SARS-CoV-2 environmental sampling is currently being implemented on college campuses
111 (wastewater) and in LTCFs (surface swabs) to identify and prevent potential outbreaks in high
112 density living situations^{20,41-44}. Wastewater surveillance is suited to detect the presence of SARS-
113 CoV-2 in a large geographic region, possibly down to the scale of a cluster of buildings or a
114 single building, but less likely to provide spatial resolution down to specific zones or rooms

115 within a building^{45,46}. Furthermore, not all occupants use restrooms while occupying public
116 buildings, increasing the possibility of missing infected occupants. Surface swabs are suited to
117 capture a time integrated exposure within a space, but effectiveness may vary depending on
118 cleaning practices, and may not detect viral RNA that remained suspended in aerosols long
119 enough for the room air to be exchanged from a space before settling could occur. Moreover,
120 based on room air fluid dynamics, uneven spatial settling likely occurs⁴⁷ and depending on the
121 number and spatial resolution of surface swab or settling plate samples collected, these methods
122 may not reflect the dynamic aerosol viral load. Each method of sampling has strengths and
123 limitations, and environmental surveillance may ultimately be most effective if implemented in
124 an integrated fashion; however, at present, little surveillance has been routinely conducted via
125 bioaerosol sampling. With the growing evidence that COVID-19 is spread through virus-
126 containing aerosol emissions and the known limitations of other environmental surveillance
127 techniques of SARS-CoV-2, it may be beneficial to supplement these with a sensitive and robust
128 bioaerosol sampling platform. To explore this question, we initiated a field study within a
129 healthcare environment including environmental sampling via surface swabs, settling plates, and
130 an active air sampler to explore the relationships of these sampling approaches.

131
132 As an environmental sampling testbed, healthcare facilities provide an excellent opportunity to
133 identify surface and aerosol contamination in rooms where viral particles may be emitted from
134 patients^{11,48–55}, while also a suitable challenge due to enhanced decontamination protocols.

135 Among built environments, healthcare facilities have some of the most advanced strategies to
136 reduce pathogen transmission risk indoors, including high air exchange rates⁵⁶, high filtration
137 efficiency, isolation environments and access to personal protective equipment (PPE), and

138 established hand hygiene practices⁵⁷. Nonetheless, current literature suggests that transmission
139 stemming from hospital-associated infections range from 14.1%-41% of in-house COVID-19
140 cases⁵⁸⁻⁶⁰, further justifying healthcare facilities as an environmental surveillance testbed.
141
142 Horve et al. conducted benchtop and room-scale experiments to determine the feasibility of air
143 sampling as an environmental surveillance tool⁶¹. Specifically, they reported that AerosolSense
144 (Thermo Fisher Scientific, Catalog #2900-AA) had robust detection capability for heat-
145 inactivated SARS-CoV-2 at aerosol viral concentrations of ~30 genome copies per liter (gc/L) of
146 room air for 75 minute sampling periods and as little as ~0.01 gc/L of room air for >8 hour
147 sampling periods⁶¹. From November to December 2020, we collected environmental surface
148 swabs and passive air settling plates from COVID-19 patient rooms at Oregon Health & Science
149 University (OHSU) Hospital in Portland, Oregon. Simultaneously, we collected air samples
150 using the AerosolSense. The objective of this study was to determine effectiveness of the
151 AerosolSense air sampler to detect SARS-CoV-2 and to better understand the relationship
152 between air and surface sampling in the built environment.

153

154 **Methods**

155 Environmental samples were collected from COVID-19 patient rooms (n=32) at OHSU from
156 November 2020 to December 2020. Factors for choosing patient rooms were severity of illness,
157 type of oxygen support and planned or anticipated aerosol generating procedures. These COVID-
158 19 positive patients were determined through either an initial rapid SARS-CoV-2 antigen test
159 followed by a RT-PCR diagnostic test or a RT-PCR diagnostic test only. COVID-19 positive
160 patients were housed in wards 5A (Acute Care), 5C (Family Medicine), 8D (Emergency

161 Department), 7A (MICU), 12C (Labor and Delivery), and 14C (Internal Medicine Inpatient). All
162 OHSU PPE donning, doffing and safety procedures were strictly followed to prevent
163 contamination and illness to healthcare workers (HCW) and/or researchers.

164

165 *Bioaerosol sampling*

166 AerosolSense instruments were calibrated to sample 200 liters per minute (L/min) of room air
167 across AerosolSense Capture Media (ACM) using the Streamline Pro MultiCal System (Chinook
168 Engineering, Wyoming). The air sampling devices were deployed in COVID-19 patient rooms
169 and allowed to run for at least one hour, with the majority of sampling events lasting in excess of
170 two hours. After sampling, the ACM was placed into a lysis/preservative buffer (DNA/RNA
171 Shield, Zymo Research #R1100) for immediate preservation of nucleic acids, and the sampling
172 run time was recorded. After each sampling event, the device was decontaminated using
173 Cavicide (Metrex), allowing a 2 minute period for the Cavicide to inactivate microorganisms,
174 and then removed from the patient room. The device was then cleaned again using Sani-Cloth
175 Bleach Germicidal Wipes (PDI #U26595).

176

177 *Surface Swab and Settling Plate Sampling*

178 At the end of the air sampling duration, surface swab samples were taken from multiple surfaces
179 in COVID-19 patient rooms using 15mL conical tubes (Cole-Parmer UX-06336-89) and
180 polyester flocked swabs (Puritan #25-3060-H) pre-moistened with Viral Transport Media (VTM)
181 (Rocky Mountain Biologicals) from the tube. A predesignated sampling area was swabbed in an
182 overlapping “S” pattern, first horizontally then vertically, to ensure complete coverage of the
183 area. The moistened swab was also rotated during collection so that optimal surface area of the

184 swab was used for sample collection and then returned to the conical tube with the remaining
185 VTM. The sampling area was approximately 20 cm by 30 cm on patient room surfaces and
186 included: work counter, return air grille, supply air grille, hopper sink, floor patient left, floor
187 patient right, floor patient foot, floor patient head (when possible), lavatory floor, lavatory
188 exhaust air grille and hallway floor immediately outside patient room. In ICU rooms, there is no
189 designated lavatory, and the sluice sink was swabbed instead. After taking a sample, the swab
190 was then returned to the 15mL conical tube containing the remainder of VTM. Sample tubes
191 were placed on ice in a designated sample cooler until processing. Settling plate samples were
192 collected from work counters, windowsills, supply carts, nurses stations, under the patient's bed,
193 and various locations on the floor of the occupied rooms. Standard petri dishes (100 mm x 15
194 mm) were set out with both halves open for the entire active air sampling duration. At sample
195 collection, the inside surface of both halves of the petri dish were swabbed as described above.

196

197 *Sample processing*

198 The sample cooler was hand carried to a BSL-2+ lab on the OHSU campus for processing. All
199 sample processing was conducted in a class-2 biosafety cabinet (BSC). The environmental
200 surface samples (flocked swabs and passive settling plates) previously placed in 15 ml conical
201 tubes were vortexed briefly and then incubated at room temperature for five minutes. A 200 μ L
202 aliquot of the supernatant was removed and placed into a microcentrifuge tube (Thomas
203 Scientific #1223K29) containing 600 μ L of lysis/preservative buffer (DNA/RNA Shield, Zymo
204 Research #2100). Samples were then transported by automobile to a BSL-2 laboratory on the
205 University of Oregon campus in Eugene, Oregon, USA. Total RNA was extracted from all
206 samples using Zymo Quick-DNA/RNA Viral MagBead kit (Zymo Research #R2141) and stored

207 at -80°C until analysis. Successful RNA extraction was confirmed using a 5 uL spike-in of
208 *Escherichia coli* MS2 bacteriophage that was added to each reaction mixture.

209

210 *Molecular Analysis*

211 SARS-CoV-2 RNA presence and abundance was determined by qRT-PCR. The TaqPath
212 COVID-19 Combo Kit (Thermo Fisher Scientific, Catalog #A47814) targeting the N, S, and
213 ORF1ab (RdRP) gene regions was used to prepare qRT-PCR reactions for processing. Each
214 reaction mixture contained 5 µL TaqPath 1-Step Multiplex Mastermix without ROX (Thermo
215 Fisher Scientific, Catalog #A28521), 9 µL nuclease-free water (Invitrogen, Catalog #4387936), 1
216 µL COVID-19 Real Time PCR Assay Multiplex Mix (Thermo Fisher Scientific, Catalog
217 #A47814), and 5 µL of extracted RNA. Thermocycling was performed with the QuantStudio5
218 (Applied Biosystems) using the following cycling conditions: 25°C for 2 minutes, 53°C for 10
219 minutes, 95°C for 2 minutes, and 40 cycles of 95°C for 3 seconds and 60°C for 30 seconds. If the
220 presence of SARS-CoV-2 RNA was detected, and the cycle threshold (C_t) was less than 35, with
221 observed amplification in two out of the three genome targets, then a sample was considered
222 positive. This follows the FDA Emergency-Use Authorization guidelines in the assay
223 instructions for use⁶². Two control samples were included in the qRT-PCR reaction. These
224 consisted of an extraction control from the RNA extraction process and a non-template control
225 (NTC) to account for possible laboratory contamination. Reagent controls were processed
226 concurrently with environmental samples. All controls tested negative for the presence of SARS-
227 CoV-2 RNA.

228

229

230 *Institutional Approval and Data Availability*

231 The research described was determined to be IRB exempt and granted an IRB exemption. This
232 work was reviewed by the OHSU Institutional Biosafety Committee and approved under
233 PROTO202000016. Data and analysis scripts are available on GitHub
234 (<https://github.com/BioBE/AerosolSense-FieldTrials>).

235

236 *Statistical Analyses*

237 All analyses were performed using the statistical computing environment, R⁶³. Differences
238 between samples from the same room were computed using paired t-tests. Differences were
239 considered significant with $P < 0.05$.

240

241 **Results**


242 The overall objective of this investigation was to explore integrated environmental surveillance
243 and to determine the potential efficacy of the AerosolSense active air sampler for the detection of
244 SARS-CoV-2-containing aerosols in a real-world setting. To this end, 39 aerosol samples
245 collected, 132 passive air samples were collected in settling plates, and 317 surface samples were
246 collected with flocked swabs from 32 COVID-19 patient rooms at OHSU over a two month
247 sampling period. All sampling locations were assessed for the percent of samples that returned a
248 positive result for the presence of SARS-CoV-2 (Figure 1). Positive samples were returned for
249 53.8% of air samples, 12.1% of passive settling plates, and 14.8% of room surface swabs. After
250 the active air samples (53.8% positive), the most frequent positive sample locations were swabs
251 taken from the floor to left side of the patient bed (25.0%), the hallway floor directly outside the

252 patient room (~21.4%), settling plates in the hallway outside the patient rooms (20.0%), and the
253 lavatory exhaust air grille (20.0%).

254

255 Overall, all three sampling types (active air, swabs, settling plates) were able to successfully
256 isolate SARS-CoV-2 RNA (Figure 2). In order to assess the potential for genomic material
257 capture differences, and ultimately to better understand sampling methods for environmental
258 viral surveillance, sampling method was compared for all rooms that returned any positive result
259 whatsoever. In total, about 69% (22/32) of sampled rooms had a positive environmental sample
260 of any type. Among these rooms, 32% (7/22) had only the air samples that returned positive,
261 27% (6/22) had only one or more surface swabs that returned positive, 9% (2/22) had only
262 passive settling plates return a positive result, and 32% (7/32) had multiple sample types that
263 returned positive. Additionally, among the 7 rooms that returned positive for both air and surface
264 swab(s), positive samples collected by the air sampler were found to have significantly lower C_t
265 values (Paired t-test; $P < 0.05$) than positive environmental surface swabs (Figure 3).

266



267

268

269

270


271

272

273

274


Figure 1. Percent of samples found to be positive for the presence of SARS-CoV-2 RNA at each location sampled. The number of total samples collected are listed at the top of each bar. A full description of each sampling location can be found in the supplementary data. Pink indicates the active air sampler, blue indicates the passive air settling plates, and green indicates surface swabs. Sampling locations with fewer than seven (n=7) were excluded from this figure.



275

276

277 **Figure 2. Room plan of one sampled patient room indicating sampling type, number and**
278 **location. Cycle threshold (Ct) values from qRT-PCR test results are included, with lower**
279 **values indicating higher abundances of SARS-CoV-2 RNA. Rectangles indicate**
280 **AerosolSense samplers, blue circles indicate passive air settling plates, and red circles**
281 **indicate surface swab locations. Filled circles indicate a positive result and open circles**
282 **indicate a negative result. This room had a positive active air sample, charting computer**
283 **swab, and windowsill settling plate.**



284
285 **Figure 3. Box and whisker plot demonstrating the minimum, maximum, median, and**
286 **quartiles C_t values observed in samples recovered from the AerosolSense sampler or**
287 **environmental swabs, among rooms that returned positive for both sampling types. Lines**
288 **connect the mean C_t value of positive samples taken from the same patient room at the**
289 **same sampling time. Positively sloped lines indicate a lower C_t value (higher abundance) of**
290 **SARS-CoV-2 RNA in air samples. Pink points are the mean (if applicable) of the C_t values**
291 **of samples collected with the air sampler and green points are the mean of all the positive**
292 **surface swabs from a given room.**

293

294

295 Discussion

296 This study contains a few important limitations. Aerosol sampling durations were variable (1-
297 12.75 hours) in order to prioritize the schedule and activities of the care team providing patient
298 care. Approximately 81% of study rooms (26/32) had one air sampler while approximately 19%
299 of the rooms (6/32) had two air samplers during the sampling period. All rooms with two air
300 samplers returned the same result for both samplers. Verified hospital room air exchange rate
301 was not available for every patient room studied. The analysis methods cannot ensure that RNA
302 detected in any room came solely from the patient occupying the room. Finally, our results report
303 the presence of SARS-CoV-2 RNA, and do not address viability, since qRT-PCR does not
304 distinguish viable virions from RNA from non-viable cells.

305
306 Overall, we sought to identify the potential utility of the AerosolSense device for active air
307 environmental surveillance and used a healthcare setting as the testbed. The active air samples
308 recovered were compared to the current standard for indoor environmental surveillance, flocked
309 environmental swabs and passive air settling plates⁶⁴⁻⁶⁷. We confirmed the results of previous
310 studies that demonstrated significant environmental contamination by SARS-CoV-2 in rooms
311 occupied by COVID-19 positive patients^{14,50,54,64,68}. While one may expect more consistent
312 detection of SARS-CoV-2 RNA in rooms occupied by COVID-19 positive patients, shedding
313 has been shown to vary by individual and decrease, even as symptoms and disease progresses⁶⁹
314 and our results are consistent with other investigations^{14,54}. Furthermore, at this facility patient
315 rooms maintain at least six air changes per hour (sometimes much higher), COVID-19 patients
316 are placed into negative pressure isolation rooms whenever possible, and all COVID-19 patient

317 rooms undergo rigorous daily cleaning protocols, all with the intention of reducing overall
318 environmental contamination.

319

320 Our data demonstrated significantly lower C_t values in samples collected from the air sampler
321 compared to environmental swabs, among rooms where both sampling methods returned a
322 positive result. The lower paired C_t values observed in the air sampler and the higher percentage
323 of positive air samples (~54%) when compared to other sampling methods, along with its ability
324 to detect SARS-CoV-2 in some rooms where other methods did not (32%), suggests that
325 bioaerosol surveillance of SARS-CoV-2 makes an important contribution to environmental viral
326 surveillance techniques. Nonetheless, there was reasonable concordance between active air
327 samples and surface swabs, with both sampling methods signaling room contamination for 32%
328 of rooms that tested positive. As stated, there was a meaningful additional percentage (32%) of
329 positive rooms were only detected via active air sampling, while 27% of positive rooms were
330 only detected via surface swabs, thus supporting the value of integrated surveillance. Surface
331 swabs and settling plate collection methods benefitted from greater number and spatial resolution
332 and sample number, while the active air sampler benefitted from continuous sampling and spatial
333 integration via mixing of room air. Furthermore, surface swab samples capture a time-integrated
334 history of direct contact and particle deposition that occurred since previous decontamination,
335 while active air samples represent a specific sampling duration, volume of air, and have an
336 opportunity to capture particles that do not deposit onto surfaces.

337

338 Overall, the air samples had the most prevalence (by percentage) of detecting SARS-CoV-2. The
339 patient room sampling locations that had the second most prevalence of detecting SARS-CoV-2

340 were surface swabs that were collected near the patient (floor adjacent to bed and mayo stand)
341 and from areas where SARS-CoV-2 was likely sourced through aerosols (patient room return air
342 grille and lavatory exhaust air grille). It is expected that areas nearer the patient (such as the
343 mayo stand, bedside table, and floor samples) would exhibit surface contamination, however the
344 prevalence of return and exhaust air grilles is less commonly reported^{54,70}. The contamination
345 observed in hallways (swabs 21.4% and settling plates 20.0%) was possibly sourced from within
346 the adjacent patient room and further spread by airflow, HCW foot traffic, or the movement of
347 equipment carts necessary for care^{71,72}, or may have been sourced from outside the patient room.
348 We observed viral contamination on low-touch surfaces (return air grilles, supply air grilles, and
349 windowsills). These locations are beyond the expected range of routine droplet transport, rarely
350 come into contact with individuals, and may not be routinely decontaminated. The supply air
351 grilles that tested positive (16.7%) may have been contaminated with SARS-CoV-2 from
352 recirculation of building ventilation air⁷³, from non-laminar flow of supply air out of the grille, or
353 potentially form within-room surface deposition or impaction sourced from high velocity
354 droplet generating events.

355
356 The presence of SARS-CoV-2 RNA in the active air samples and upon surfaces that are
357 commingled with active room airflow (supply, return, and exhaust air grilles), combined with the
358 growing evidence of the potential for aerosol-based disease transmission^{16,20,53,66,73–81}, presents a
359 compelling argument for the merit of indoor air microbial surveillance. Moreover, due to the
360 spatially integrated nature of indoor aerosols, continuous air sampling techniques with sufficient
361 sensitivity can be incredibly useful to increase situational awareness and guide building
362 operational improvements to reduce indoor disease transmission risk⁸².

363

364 When encountered with a possible infectious disease outbreak, epidemic or pandemic, healthcare
365 facilities and government public health agencies respond with containment strategies. This
366 response strategy is well documented by most global governing bodies with a structured
367 healthcare system. The steps of infectious agent containment include: 1) identification of agent
368 2) infection control assessment 3) health screenings where appropriate 4) coordinated response
369 efforts and 5) continued assessments and health screenings until containment is achieved⁸³. Built
370 environment surveillance in general, and active air monitoring in specific, should be an integral
371 and proactive component of a comprehensive infectious disease management strategy. By
372 pairing these surveillance data with appropriate building operations layered risk reduction
373 strategies, the transmission of disease indoors can be minimized and potentially avoided.

374

375 **Conclusion**

376 Currently, the majority of environmental surveillance for microorganisms utilize wastewater and
377 surface sampling. Wastewater, surface swabs, and aerosol surveillance methods each have
378 strengths and limitations, and are best implemented in an integrated manner. Wastewater
379 sampling provides excellent insight to larger geographic scales disease prevalence but has
380 limitations for guiding actions within a specific facility. Surface samples are time-integrated and
381 are influenced by decontamination protocols, as well as spatial resolution and room air
382 dynamics. This research demonstrates the added detection capability of bioaerosol sampling in
383 environmental viral surveillance. Specifically, this research demonstrates that the AerosolSense
384 active bioaerosol sampling platform effectively detects SARS-CoV-2 RNA in a real-world
385 healthcare environment with high air exchange rates.

386

387 **Acknowledgements**

388 Gratitude for the Biology and the Built Environment Laboratory students Liliana Barnata and
389 Vincent Moore, who assisted with sample collection on-site. A special thanks to staff Georgia
390 MacCrone and Surbhi Nahata, who assisted with the lab work. The authors would like to thank
391 Siqu Tan, Arunava Dutta, and Geoffrey Gonzalez for their review of the manuscript.
392 Lastly, special recognition for the many frontline health care workers, who provide tireless and
393 compassionate care for their patients.

394

395 **References**

- 396 1. Cucinotta, D. & Vanelli, M. WHO Declares COVID-19 a Pandemic. *Acta Biomed.* **91**, 157–
397 160 (2020).
- 398 2. Johansson, M. A. *et al.* SARS-CoV-2 Transmission From People Without COVID-19
399 Symptoms. *JAMA Netw Open* **4**, e2035057 (2021).
- 400 3. Stadnytskyi, V., Bax, C. E., Bax, A. & Anfinrud, P. The airborne lifetime of small speech
401 droplets and their potential importance in SARS-CoV-2 transmission. *Proc. Natl. Acad. Sci.*
402 *U. S. A.* **117**, 11875–11877 (2020).
- 403 4. CDC. COVID-19 and Your Health. [https://www.cdc.gov/coronavirus/2019-ncov/prevent-](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html)
404 [getting-sick/how-covid-spreads.html](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html) (2021).
- 405 5. Organization, W. H. & Others. *Modes of transmission of virus causing COVID-19:*
406 *implications for IPC precaution recommendations: scientific brief, 27 March 2020.*
407 [https://apps.who.int/iris/bitstream/handle/10665/331601/WHO-2019-nCoV-Sci_Brief-](https://apps.who.int/iris/bitstream/handle/10665/331601/WHO-2019-nCoV-Sci_Brief-Transmission_modes-2020.1-eng.pdf)
408 [Transmission_modes-2020.1-eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/331601/WHO-2019-nCoV-Sci_Brief-Transmission_modes-2020.1-eng.pdf) (2020).

- 409 6. Prather, K. A. *et al.* Airborne transmission of SARS-CoV-2. *Science* **370**, 303–304 (2020).
- 410 7. Allen, J. G. & Marr, L. C. Recognizing and controlling airborne transmission of SARS-
411 CoV-2 in indoor environments. *Indoor Air* vol. 30 557–558 (2020).
- 412 8. Adhikari, U. *et al.* A case study evaluating the risk of infection from Middle Eastern
413 Respiratory Syndrome Coronavirus (MERS-CoV) in a Hospital Setting Through
414 Bioaerosols. *Risk Anal.* **39**, 2608–2624 (2019).
- 415 9. Riley, S. *et al.* Transmission dynamics of the etiological agent of SARS in Hong Kong:
416 impact of public health interventions. *Science* **300**, 1961–1966 (2003).
- 417 10. Tran, K., Cimon, K., Severn, M., Pessoa-Silva, C. L. & Conly, J. Aerosol generating
418 procedures and risk of transmission of acute respiratory infections to healthcare workers: a
419 systematic review. *PLoS One* **7**, e35797 (2012).
- 420 11. Yu, I. T. *et al.* Why did outbreaks of severe acute respiratory syndrome occur in some
421 hospital wards but not in others? *Clin. Infect. Dis.* **44**, 1017–1025 (2007).
- 422 12. Morawska, L. & Cao, J. Airborne transmission of SARS-CoV-2: The world should face the
423 reality. *Environ. Int.* **139**, 105730 (2020).
- 424 13. van Doremalen, N. *et al.* Aerosol and Surface Stability of SARS-CoV-2 as Compared with
425 SARS-CoV-1. *N. Engl. J. Med.* **382**, 1564–1567 (2020).
- 426 14. Ong, S. W. X. *et al.* Air, Surface Environmental, and Personal Protective Equipment
427 Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From
428 a Symptomatic Patient. *JAMA* (2020) doi:10.1001/jama.2020.3227.
- 429 15. Wu, S. *et al.* Environmental contamination by SARS-CoV-2 in a designated hospital for
430 coronavirus disease 2019. *Am. J. Infect. Control* **48**, 910–914 (2020).
- 431 16. Wang, J. *et al.* Prevention and control of COVID-19 in nursing homes, orphanages, and

- 432 prisons. *Environ. Pollut.* **266**, 115161 (2020).
- 433 17. Nabarro, D., DeLand, K. & Lasbennes, F. COVID in cold environments: risks in meat
434 processing plants. *iuf.org*.
- 435 18. Leclerc, Q. J. *et al.* What settings have been linked to SARS-CoV-2 transmission clusters?
436 *Wellcome Open Res.* **5**, 83 (2020).
- 437 19. Qian, H. *et al.* Indoor transmission of SARS-CoV-2. *Indoor Air* (2020)
438 doi:10.1111/ina.12766.
- 439 20. Dumont-Leblond, N. *et al.* Positive no-touch surfaces and undetectable SARS-CoV-2
440 aerosols in long-term care facilities: An attempt to understand the contributing factors and
441 the importance of timing in air sampling campaigns. *Am. J. Infect. Control* (2021)
442 doi:10.1016/j.ajic.2021.02.004.
- 443 21. *Mays v. Dart. F. Supp. 3d* vol. 453 1074 (2020).
- 444 22. Yang, H. & Thompson, J. R. Fighting covid-19 outbreaks in prisons. *BMJ* vol. 369 m1362
445 (2020).
- 446 23. The-COVID-Jungle.pdf.
- 447 24. Sun, Y., Wang, Z., Zhang, Y. & Sundell, J. In China, students in crowded dormitories with
448 a low ventilation rate have more common colds: evidence for airborne transmission. *PLoS*
449 *One* **6**, e27140 (2011).
- 450 25. Killian, J., Meyer, E. A., Chang, J., Dressen, S. & Eyring, G. *Sensor Systems for Biological*
451 *Agent Attacks: Protecting Buildings and Military Bases*.
452 <https://apps.dtic.mil/sti/pdfs/ADA457006.pdf> (2004).
- 453 26. Walper, S. A. *et al.* Detecting Biothreat Agents: From Current Diagnostics to Developing
454 Sensor Technologies. *ACS Sens* **3**, 1894–2024 (2018).

- 455 27. Microbial analysis. https://ww2.health.wa.gov.au/Articles/J_M/Microbial-analysis.
- 456 28. CDC. Performing Facility-wide SARS-CoV-2 Testing in Nursing Homes.
457 <https://www.cdc.gov/coronavirus/2019-ncov/hcp/nursing-homes-facility-wide-testing.html>
458 (2020).
- 459 29. Legionnaires Disease Outbreak Considerations. [https://www.cdc.gov/legionella/health-](https://www.cdc.gov/legionella/health-depts/epi-resources/outbreak-investigations.html)
460 [depts/epi-resources/outbreak-investigations.html](https://www.cdc.gov/legionella/health-depts/epi-resources/outbreak-investigations.html) (2021).
- 461 30. National Academy of Science, Engineering and Medicine. *Management of Legionella in*
462 *Water Systems*. (The National Academies Press, 2020).
- 463 31. Sogin, J. H. *et al.* Implementation of ATP and Microbial Indicator Testing for Hygiene
464 Monitoring in a Tofu Production Facility Improves Product Quality and Hygienic
465 Conditions of Food Contact Surfaces: A Case Study. *Appl. Environ. Microbiol.* (2020)
466 doi:10.1128/AEM.02278-20.
- 467 32. Cooper, R. A., Griffith, C. J., Malik, R. E., Obee, P. & Looker, N. Monitoring the
468 effectiveness of cleaning in four British hospitals. *Am. J. Infect. Control* **35**, 338–341
469 (2007).
- 470 33. Scherer, K. *et al.* Application of a Swab Sampling Method for the Detection of Norovirus
471 and Rotavirus on Artificially Contaminated Food and Environmental Surfaces. *Food*
472 *Environ. Virol.* **1**, 42 (2009).
- 473 34. McCarthy, A. *et al.* Ultra-absorptive Nanofiber Swabs for Improved Collection and Test
474 Sensitivity of SARS-CoV-2 and other Biological Specimens. *Nano Lett.* **21**, 1508–1516
475 (2021).
- 476 35. Fan, Z.-H. T. Passive Air Sampling: Advantages, Limitations, and Challenges.
477 *Epidemiology* **22**, S132 (2011).

- 478 36. Pasquarella, C., Pitzurra, O. & Savino, A. The index of microbial air contamination. *J.*
479 *Hosp. Infect.* **46**, 241–256 (2000).
- 480 37. Napoli, C., Marcotrigiano, V. & Montagna, M. T. Air sampling procedures to evaluate
481 microbial contamination: a comparison between active and passive methods in operating
482 theatres. *BMC Public Health* **12**, 594 (2012).
- 483 38. Li, K. Molecular comparison of the sampling efficiency of four types of airborne bacterial
484 samplers. *Sci. Total Environ.* **409**, 5493–5498 (2011).
- 485 39. Sandle, T. Selection of active air samplers. *European Journal of Parenteral and*
486 *Pharmaceutical Sciences* **15**, 119–124 (2010).
- 487 40. Raynor, P. C. Toward Identifying the Most Effective Samplers for Airborne Viruses.
488 (2018).
- 489 41. Denny, T. N. *et al.* Implementation of a Pooled Surveillance Testing Program for
490 Asymptomatic SARS-CoV-2 Infections on a College Campus - Duke University, Durham,
491 North Carolina, August 2-October 11, 2020. *MMWR Morb. Mortal. Wkly. Rep.* **69**, 1743–
492 1747 (2020).
- 493 42. Case study-whitepaper - enviral tech - COVID surface testing. [https://enviraltech.com/case-](https://enviraltech.com/case-study-whitepaper/)
494 [study-whitepaper/](https://enviraltech.com/case-study-whitepaper/) (2020).
- 495 43. Harris-Lovett, S. *et al.* Wastewater surveillance for SARS-CoV-2 on college campuses:
496 Initial efforts, lessons learned and research needs. *medRxiv* (2021)
497 doi:10.1101/2021.02.01.21250952.
- 498 44. Betancourt, W. W. *et al.* Wastewater-based epidemiology for averting COVID-19 outbreaks
499 on the University of Arizona campus. *bioRxiv* (2020) doi:10.1101/2020.11.13.20231340.
- 500 45. Peccia, J. *et al.* Measurement of SARS-CoV-2 RNA in wastewater tracks community

- 501 infection dynamics. *Nat. Biotechnol.* **38**, 1164–1167 (2020).
- 502 46. Randazzo, W. *et al.* SARS-CoV-2 RNA in wastewater anticipated COVID-19 occurrence in
503 a low prevalence area. *Water Res.* **181**, 115942 (2020).
- 504 47. Nazaroff, W. W. Indoor particle dynamics. *Indoor Air* **14 Suppl 7**, 175–183 (2004).
- 505 48. Guo, Z.-D. *et al.* Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome
506 Coronavirus 2 in Hospital Wards, Wuhan, China, 2020. *Emerg. Infect. Dis.* **26**, 1583–1591
507 (2020).
- 508 49. Coil, D. A. *et al.* SARS-CoV-2 detection and genomic sequencing from hospital surface
509 samples collected at UC Davis. *bioRxiv* (2021) doi:10.1101/2021.02.23.21252022.
- 510 50. Ye, G. *et al.* Environmental contamination of SARS-CoV-2 in healthcare premises. *J.*
511 *Infect.* **81**, e1–e5 (2020).
- 512 51. Zhou, J. *et al.* Investigating SARS-CoV-2 surface and air contamination in an acute
513 healthcare setting during the peak of the COVID-19 pandemic in London. *Clin. Infect. Dis.*
514 (2020) doi:10.1093/cid/ciaa905.
- 515 52. Redmond, S. N. *et al.* Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
516 nucleic acid contamination of surfaces on a coronavirus disease 2019 (COVID-19) ward
517 and intensive care unit. *Infect. Control Hosp. Epidemiol.* **42**, 215–217 (2021).
- 518 53. Lednicky, J. A. *et al.* Viable SARS-CoV-2 in the air of a hospital room with COVID-19
519 patients. *Int. J. Infect. Dis.* **100**, 476–482 (2020).
- 520 54. Santarpia, J. L. *et al.* Aerosol and surface contamination of SARS-CoV-2 observed in
521 quarantine and isolation care. *Sci. Rep.* **10**, 12732 (2020).
- 522 55. Liu, Y. *et al.* Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. *Nature* **582**,
523 557–560 (2020).

- 524 56. ANSI/ASHRAE/ASHE Standard 170-2017, Ventilation of Health Care Facilities.
525 <https://www.ashrae.org/technical-resources/standards-and-guidelines/standards->
526 [addenda/ansi-ashrae-ashe-standard-170-2017-ventilation-of-health-care-facilities](https://www.ashrae.org/technical-resources/standards-and-guidelines/standards-addenda/ansi-ashrae-ashe-standard-170-2017-ventilation-of-health-care-facilities).
- 527 57. Hor, S.-Y. *et al.* Beyond hand hygiene: a qualitative study of the everyday work of
528 preventing cross-contamination on hospital wards. *BMJ Qual. Saf.* **26**, 552–558 (2017).
- 529 58. Meredith, L. W. *et al.* Rapid implementation of real-time SARS-CoV-2 sequencing to
530 investigate healthcare-associated COVID-19 infections. *MedRxiv* (2020).
- 531 59. Van Praet, J. T., Claeys, B., Coene, A.-S., Floré, K. & Reynders, M. Prevention of
532 nosocomial COVID-19: Another challenge of the pandemic. *Infect. Control Hosp.*
533 *Epidemiol.* **41**, 1355–1356 (2020).
- 534 60. Wang, X. *et al.* Nosocomial outbreak of COVID-19 pneumonia in Wuhan, China. *Eur.*
535 *Respir. J.* **55**, (2020).
- 536 61. Horve, P. F., Dietz, L., Northcutt, D., Stenson, J. & Van Den Wymelenberg, K. G.
537 Evaluation of a Bioaerosol Sampler for Indoor Environmental Surveillance of Severe Acute
538 Respiratory Syndrome Coronavirus 2. (2021) doi:10.20944/preprints202103.0609.v1.
- 539 62. TaqPath COVID-19 Combo Kit Instructions for Use (Pub.No. MAN0019181 A.0).
- 540 63. Core, R. Team. *R: a language and environment for statistical computing* **3**, 2 (2015).
- 541 64. Hermes, A. C. *et al.* Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
542 Environmental Contamination and Childbirth. *Obstet. Gynecol.* **136**, 827–829 (2020).
- 543 65. Horve, P. F. *et al.* Viable bacterial communities on hospital window components in patient
544 rooms. *PeerJ* **8**, e9580 (2020).
- 545 66. Santarpia, J. L. *et al.* Transmission potential of SARS-CoV-2 in viral shedding observed at
546 the University of Nebraska Medical Center. *MedRxiv* (2020).

- 547 67. Rönqvist, M., Rättö, M., Tuominen, P., Salo, S. & Maunula, L. Swabs as a tool for
548 monitoring the presence of norovirus on environmental surfaces in the food industry. *J.*
549 *Food Prot.* **76**, 1421–1428 (2013).
- 550 68. Chia, P. Y. *et al.* Detection of air and surface contamination by SARS-CoV-2 in hospital
551 rooms of infected patients. *Nat. Commun.* **11**, 2800 (2020).
- 552 69. van Kampen, J. J. A. *et al.* Duration and key determinants of infectious virus shedding in
553 hospitalized patients with coronavirus disease-2019 (COVID-19). *Nat. Commun.* **12**, 267
554 (2021).
- 555 70. Mouchtouri, V. A. *et al.* Environmental contamination of SARS-CoV-2 on surfaces, air-
556 conditioner and ventilation systems. *Int. J. Hyg. Environ. Health* **230**, 113599 (2020).
- 557 71. Wang, J., Zhou, M. & Liu, F. Reasons for healthcare workers becoming infected with novel
558 coronavirus disease 2019 (COVID-19) in China. *J. Hosp. Infect.* **105**, 100–101 (2020).
- 559 72. Kuy, S., Gupta, R., Correa, R., Tsai, R. & Vohra, S. Best practices for a Covid-19
560 preparedness plan for health systems. *NEJM Catalyst Innovations in Care Delivery* **1**,
561 (2020).
- 562 73. Horve, P. F. *et al.* Identification of SARS-CoV-2 RNA in Healthcare Heating, Ventilation,
563 and Air Conditioning Units. *Infectious Diseases (except HIV/AIDS)* (2020)
564 doi:10.1101/2020.06.26.20141085.
- 565 74. Miller, S. L. *et al.* Transmission of SARS-CoV-2 by inhalation of respiratory aerosol in the
566 Skagit Valley Chorale superspreading event. *Infectious Diseases (except HIV/AIDS)* (2020)
567 doi:10.1101/2020.06.15.20132027.
- 568 75. Tang, J. W. *et al.* Dismantling myths on the airborne transmission of severe acute
569 respiratory syndrome coronavirus-2 (SARS-CoV-2). *J. Hosp. Infect.* **110**, 89–96 (2021).

- 570 76. Tang, S. *et al.* Aerosol transmission of SARS-CoV-2? Evidence, prevention and control.
571 *Environ. Int.* **144**, 106039 (2020).
- 572 77. Gregson, F. K. A. *et al.* Comparing aerosol concentrations and particle size distributions
573 generated by singing, speaking and breathing. *Aerosol Sci. Technol.* 1–15 (2021)
574 doi:10.1080/02786826.2021.1883544.
- 575 78. Klompas, M., Baker, M. A. & Rhee, C. Airborne Transmission of SARS-CoV-2:
576 Theoretical Considerations and Available Evidence. *JAMA* **324**, 441–442 (2020).
- 577 79. Nissen, K. *et al.* Long-distance airborne dispersal of SARS-CoV-2 in COVID-19 wards.
578 *Sci. Rep.* **10**, 19589 (2020).
- 579 80. Hamner, L. *et al.* High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice -
580 Skagit County, Washington, March 2020. *MMWR Morb. Mortal. Wkly. Rep.* **69**, 606–610
581 (2020).
- 582 81. Majra, D., Benson, J., Pitts, J. & Stebbing, J. SARS-CoV-2 (COVID-19) superspreader
583 events. *J. Infect.* **82**, 36–40 (2021).
- 584 82. Parhizkar, H., Van Den Wymelenberg, K., Haas, C. & Corsi, R. A quantitative risk
585 estimation platform for indoor aerosol transmission of COVID-19. *medRxiv*
586 2021.03.05.21252990 (2021) doi:10.1101/2021.03.05.21252990.
- 587 83. Containment Strategy. <https://www.cdc.gov/hai/containment/index.html> (2021).
588
589